ArticleCancers2024

Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain.

Alejandro Martín García-Sancho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.